在耐火性狼性炎的三个病例中使用贝利穆马布
Aruni Malaweera1, Sukhpal Dayan2, Rebecca Pellicano1
1Department of Nephrology, Monash Health, Melbourne, Victoria, Australia.
Internal medicine journal
|October 20, 2023
概括
贝利马布 (BLM) 在不耐药性狼性炎 (LN) 病例中显示部分缓解,这些病例对其他治疗没有反应. 这种生物疗法改善了SLE标志物,并允许减少类固醇使用,突出了其在治疗严重狼性炎方面的潜力.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 系统性红斑狼 (SLE) 和狼性炎 (LN) 需要有效的治疗方法.
- 耐火性LN病例通常对标准免疫抑制剂没有反应.
- 早期干预对于预防不可逆转的损伤至关重要.
研究的目的:
- 为了评估贝利穆马布 (BLM) 在耐火性狼性炎患者的疗效.
- 评估BLM对结结果,血清学标志物和疾病活性的影响.
- 探索BLM在减少皮质类固醇依赖方面的作用.
主要方法:
- 三名耐火性LN患者的回顾性病例系列.
- 患者除了接受现有的免疫抑制疗法外,还接受了贝利马布 (BLM).
- 评估的结果包括性缓解,血清学标志物和普雷迪尼索隆剂量.
主要成果:
- 在三名患者中,有两名患者实现了狼性炎 (LN) 的部分缓解.
- 贝利马布 (BLM) 治疗导致SLE血清标志物得到改善,疾病活性降低.
- 在有反应的患者中,普雷迪尼索隆剂量成功降低.
结论:
- 贝利马布 (BLM) 显示出作为耐火性狼性炎 (LN) 的治疗潜力.
- 早期使用BLM治疗可能有助于实现缓解并减少类固醇负担.
- 需要对BLM的长期疗效,爆发预防和安全概况进行进一步的研究.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
148
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
148
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170
Inflammatory Bowel Disease IV: Pharmacological Management
134
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
134


